Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Tanaka, M. Otsuki, T. Une, T. Nishino (1990)
In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin.The Journal of antimicrobial chemotherapy, 26 5
Dagrosa Ee, M. Verho, Malerczyk, S. deLooze, P. Hajdu, K. Toyodera (1986)
Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.Clinical therapeutics, 8 6
M. Verho, V. Malerczyk, E. Dagrosa, A. Korn (1986)
The effect of food on the pharmacokinetics of ofloxacin.Current medical research and opinion, 10 3
O. Okazaki, T. Kurata, H. Hakusui, H. Tachizawa (1992)
Species-related stereoselective disposition of ofloxacin in the rat, dog and monkey.Xenobiotica; the fate of foreign compounds in biological systems, 22 4
Y. Kawada, Y. Kumamoto, Y. Aso, T. Machida, I. Saito, N. Kawamura, M. Ohkoshi, Y. Naide, K. Kawabe, H. Hisazumi, K. Okada, S. Kamidono, H. Ohmori, T. Usui, S. Kagawa, Yukitoshi Fujita, J. Kumazawa, Y. Ohi, K. Ueno, N. Ogawa (1992)
Comparative study on levofloxacin and ofloxacin in complicated urinary tract infectionsChemotherapy, 40
L. Wingard, R. O'Reilly, G. Levy (1978)
Pharmacokinetics of warfarin enantiomers: A search for intrasubject correlationsClinical Pharmacology & Therapeutics, 23
Osamu, Okazaki, Chieko Kojima, Hideo Hakusui, Mitsuyoshi Nakashima (1991)
Enantioselective disposition of ofloxacin in humansAntimicrobial Agents and Chemotherapy, 35
T. Une, T. Fujimoto, Kenichi Sato, Y. Osada (1988)
In vitro activity of DR-3355, an optically active ofloxacinAntimicrobial Agents and Chemotherapy, 32
G. Cotzias, P. Papavasiliou, R. Gellene (1969)
Modification of Parkinsonism--chronic treatment with L-dopa.The New England journal of medicine, 280 7
N. Lameire, B. Rosenkranz, V. Malerczyk, K. Lehr, N. Veys, S. Ringoir (1991)
Ofloxacin Pharmacokinetics in Chronic Renal Failure and DialysisClinical Pharmacokinetics, 21
M. Imamura, S. Shibamura, I. Hayakawa, Y. Osada (1987)
Inhibition of DNA gyrase by optically active ofloxacinAntimicrobial Agents and Chemotherapy, 31
H. Goossens, P. Mol, H. Coignau, J. Levy, O. Grados, G. Ghysels, H. Innocent, J. Butzler (1985)
Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogensAntimicrobial Agents and Chemotherapy, 27
M. Eichelbaum, G. Mikus, B. Vogelgesang (1984)
Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.British journal of clinical pharmacology, 17 4
W. Cullmann, M. Stieglitz, B. Baars, W. Opferkuch (1985)
Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.Chemotherapy, 31 1
M. Verho, V. Malerczyk, E. Dagrosa, A. Korn (1985)
Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent.Pharmatherapeutica, 4 6
H. Passing, W. Bablok (1983)
A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part I, 21
Karl-Heinz Lehr, Petra Damm (1988)
Quantification of the enantiomers of ofloxacin in biological fluids by high-performance liquid chromatography.Journal of chromatography, 425 1
I. Ho, R. Harris (1981)
Mechanism of action of barbiturates.Annual review of pharmacology and toxicology, 21
(1984)
Pharmakokinetik von Ofloxacin (HOE 280)
I. Hayakawa, S. Atarashi, S. Yokohama, M. Imamura, K. Sakano, M. Furukawa (1986)
Synthesis and antibacterial activities of optically active ofloxacinAntimicrobial Agents and Chemotherapy, 29
J. Wagner (1975)
Fundamentals of Clinical Pharmacokinetics
M. Verho1, V. Malerczyk2, D. Damm3 and K.-H. Lehr3 'Clinical Research, 2Clinical Research/Biometrics, 3 Department of Pharma Research, Biochemistry, Hoechst AG, D-65926 Frankfurt, Germany SUMMARY After oral administration of a single dose of 200 mg of levofloxacin and 400 mg racemic mixture of ofloxacin to 6 healthy male volunteers in a double-blind, randomised cross-over study, concentrations of the unchanged isomers were determined at various times in serum and urine, over 28 hours and 48 hours, respectively. Each dosing was followed by a wash-out period of one week. Ofloxacin concentrations were determined using an enantioselective and a non-enantioselective high pressure liquid chromatography (HPLC) assay. The two measurements obtained were compared by linear distribution independent regression, and were found to be equivalent. Maximum serum concentration (Cmax) of levofloxacin after the administration of 200 mg of the levo-isomer was 2.42 mg/1 (chiral derivatization HPLC, mean values); the corresponding area under the serum concentration-time curve (AUCo-28) was 17.0 mg Ï Î. The corresponding C m a x values after the administration of 400 mg (±)isomer (chiral derivatization HPLC and reversed phased HPLC, mean values) were 2.05 mg/1, 1.98 mg/1 and 4.41 mg/1 for (-)-, (+)- and (±) isomer, respectively. The AUCso-28 were
Drug Metabolism and Drug Interactions – de Gruyter
Published: Sep 1, 1996
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.